Mode
Text Size
Log in / Sign up
Phase 4 N=115 Randomized Single-blind Treatment

Anterior Cruciate Ligament Pain Study

Anterior Cruciate Ligament Reconstruction

Enrolled (actual)
115
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: Pain Score — 4.1; 4.0; 3.9; 5.1 units on a scale

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Ropivacaine 0.5% (Drug); Percocet 7.5/325 (Drug); Naprosyn 500 mg (Drug)
Age
Pediatric, Adult, Older Adult
Sex
All
Sponsor
Emory University
Primary completion
Apr 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain Score
4.1; 4.0; 3.9; 5.1; 5.7; 5.7
SECONDARY
Number of Percocet Tablets Consumed
2.0; 2.4; 4.6; 4.7; 3.7; 3.6
SECONDARY
Total Hours of Sleep
6.3; 5.8
SECONDARY
Patient-Reported Nausea
3; 2
SECONDARY
Patient-Reported Vomiting
1; 1
SECONDARY
Patient-Reported Constipation
2; 1
SECONDARY
Patient-Reported Sedation
0; 0
SECONDARY
Patient-Reported Itching
2; 1
SECONDARY
Time to Straight Less Raise
31.7; 16.4
SECONDARY
Percent of Patients Rating Their Satisfaction as "Excellent" or "Good"
39; 64

Summary

The objective of this study is to compare the pain control benefit of two different types of nerve blocks in patients undergoing anterior cruciate ligament (ACL) reconstruction.

Eligibility Criteria

Inclusion Criteria

  • Patients undergoing scheduled anterior cruciate ligament (ACL) surgery at the Emory Orthopaedic and Spine Center
  • Patients willing and able to provide written informed consent
  • Parents willing and able to provide written informed consent for minors

Exclusion Criteria

  • Patients who are pregnant or lactating
  • Patients with liver dysfunction or renal failure
  • Patients with a known allergy to ropivacaine
  • Patients with a local infection
  • Patients who take chronic pain medications
  • Patients with an opioid tolerance
  • Patients with known coagulopathy or bleeding risk.
  • Patients who are getting neuraxial anesthesia for surgery
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02604550). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search